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102a Sunday, February 16, 2014nucleotide Exchange Factors (GEFs), including non-receptor-like GEFs, cause
dynamic structural changes which facilitate substrate release. Although
receptor-G Protein interactions are well known a lack of understanding of
non-receptor-G protein interactions still exists, namely Ga interactions with
the non-receptor GEF Ric-8A. A 10-to-100 fold decrease in nucleotide ex-
change rate for Ric-8A compared to receptors has been shown, which begs
the question: What is the cause for the decrease between receptor and non-
receptor GEF activity? To answer this, the dynamic and structural interactions
of Ga-Ric-8A have been probed by fluorescence anisotropy and single-
molecule Fo¨rster Resonance Energy Transfer (smFRET). Conformational
changes in the ms times-scale of inter and intra-domain states and increase
segmental motions of the switch (I-III) regions seem to play a role in substrate
release.
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The epidermal growth factor receptor (EGFR) is a member of the ErbB family
of receptor tyrosine kinases which play an important role in a number of phys-
iological responses and have also been identified as a common signaling
component in several cancer types. Physiological signaling is initiated by
ligand binding which stabilizes EGFR dimers, resulting in auto-
phosphorylation of the intracellular kinase domain. Mutation of EGFR is asso-
ciated with tumor progression due to constitutive activity resulting from several
known kinase domain variants. Our previous work has shown that ligand-
induced dimerization of wild type EGFR results in decreased receptor mobility,
and that this reduction in mobility is dependent on kinase activity. Therefore,
we wondered whether ligand-independent activity of EGFR mutants correlates
with differences in receptor mobility or dimerization kinetics.
Here, we employ multi-color, single particle tracking (SPT) of quantum dots to
visualize and quantify the dynamics and interactions of individual receptors
within the membrane. Using a novel, high-speed hyperspectral microscope,
we are able to track up to eight spectrally distinct quantum dots for visualiza-
tion and quantification of receptor interactions. From this data, we quantify re-
ceptor dimerization kinetics using a Hidden Markov Model. We find that
unliganded EGFR mutants exhibit a reduced mobility and longer dimer life-
times when compared to wild type. These results are consistent with constitu-
tive activity of the EGFR mutants and suggest that the active kinase domain
facilitates dimer formation in the absence of ligand. Moreover, we test the ef-
fects of clinical tyrosine kinase inhibitors on the single molecule behavior of
EGFR mutants. We further examined the mobility and clustering of EGFR
within the cellular actin cytoskeleton by hyperspectral tracking over GFP-
actin, as well as two-color super-resolution microscopy.
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BACKGROUND AND PURPOSE. Insulin stimulates the transport of glucose
in target tissues by triggering the translocation of glucose transporter 4 (GLUT4)
to the plasma membrane. Resistance to insulin, the major abnormality in type 2
diabetes, results in a decreased GLUT4 translocation efficiency, leading to hy-
perglycemia. Thus, special attention is drawn on the search for compounds,
termed insulin mimetics, which are able to enhance this translocation process
in the absence of insulin.
EXPERIMENTAL APPROACH. In the present work Total Internal Reflection
Fluorescence (TIRF) microcopy was applied to quantify GLUT4 translocation
in highly insulin sensitive CHO-K1 cells expressing a GLUT4-myc-GFP fusion
protein. Customized software was developed to further increase the throughput
capability.
KEYRESULTS.Using our approachwe proved theGLUT4 translocation inhib-
itory properties of selected substances in live and fixed cells. In addition,we vali-
dated the efficacy of known GLUT4 translocation inducers and characterized
newsubstances,mainly phytochemicals,with potential insulinmimetic function.CONCLUSIONS AND IMPLICATIONS. Taken together, TIRF microscopy
proved to be a superior tool for the quantification of GLUT4 translocation
and the search for insulin mimetic drugs.
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The human cannabinoid receptor, CB1, a G protein-coupled receptor (GPCR),
contains a somewhat long (~110 a.a.) amino terminus. We explored a potential
role for the CB1 N-terminus in modulating ligand binding to the receptor.
Although the majority of the CB1 N-terminus is not necessary for high-
affinity ligand binding, previous studies have found that mutations introduced
into a conserved membrane proximal region (MPR) do impair the receptors
ability to bind ligand. Moreover, the highly conserved MPR (~ residues 90-
110) contains two invariant cysteine residues that are conserved in all CB1 re-
ceptors. Our data suggest these two cysteines (C98 and C107) form a disulfide
in human CB1, and this C98-C107 disulfide is more accessible to reducing
agents than the disulfide in extracellular loop 2 (EL2). The presence of the
N-terminal C98-C107 disulfide appears to modulate ligand binding to the re-
ceptor in a way that can be quantitatively analyzed by an allosteric model.
The C98-C107 disulfide also alters the effects of CB1 allosteric ligands, Org
27569 and PSNCBAM-1. Our results provide new insights to how the N-termi-
nal MPR and EL2 act together to influence the high-affinity orthosteric ligand
binding site in CB1, and suggest the CB1 N-terminal MPR may be an area
through which allosteric modulators can act.
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The active metarhodopsin II (MII) conformation of rhodopsin loses activity
when it releases its agonist, all-trans retinal, and decays to the inactive apopro-
tein, opsin. Here, we studied how the conformational change and retinal release
are linked. In our experiments, we used tryptophan induced quenching of fluo-
rescence (TrIQ) to observe movement of transmembrane helix 6 (TM6) through
an attached fluorescent probe, while simultaneously measuring intrinsic trypto-
phan fluorescence to monitor retinal release. The data show TM6 moves from
its position in the active structure back into the helical bundle in opsin (indic-
ative of the inactive conformation) with a rate matching that of retinal exit; both
processes exhibit a t1/2 of ~15 minutes at 20C in 0.05% dodecyl maltoside at
pH 6.0. We further tested the correlation of these events in two ways. First, we
carried out an Arrhenius analysis and determined near identical activation en-
ergies for TM6 resetting and retinal release (~23 kcal/mol). Additionally, we
tested the effect of altering the rate of retinal release on the rate of the confor-
mational change. The release process was slowed by introducing a mutation to
the Schiff base counterion, E113Q. When retinal exit was slowed, the rate of
TM6 resetting decelerated to the same degree. Likewise, accelerating retinal
release by using hydroxylamine to hydrolyze the Schiff base linkage caused
a corresponding acceleration of the rate of TM6 movements. With these tools
in hand, we have begun investigating the dynamics and energetic of other
movements in the protein, with the goal of constructing a more comprehensive
model for receptor deactivation following light-activation, as well as testing
how mutations (such as retinitis pigmentosa), small molecules, and other pro-
teins can effect these events.
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With almost 1000 unique G Protein Coupled Receptors (GPCR’s) mapped in
the human genome, and an estimated 40% of current marketed drugs targeting
these proteins, there is little question that it worthwhile to develop newmethods
to more efficiently screen for small molecule agonists and antagonists. One
such group of GPCRs, the endothelin receptors, is home to one of the most
potent vasoconstrictors, the Endothelin A receptor (ETA) which is an excellent
target for selective antagonists for the treatment of pulmonary arterial hyperten-
sion. We have developed a method for screening selective antagonists which
target intracellular domains of ETA and ETB using a soluble template (to
mimic a region of the transmembrane domains of ETA and ETB) fused to
